Cytek Biosciences announces preliminary unaudited revenue results for Q4 and full year 2025, expecting total revenue of $201 million for 2025.
Q4 2025 revenue of $62 million shows 8% growth YoY and 19% growth QoQ.
Positive trends include strong growth in Services, Reagents, and Asia Pacific instrument revenue, and improved instrument sales in the US and EMEA regions.
Q4 Revenue Growth
Q4 2025 revenue growth marks a significant acceleration compared to previous quarters in 2025.
Positive Trends
Strong growth in Services, Reagents, and Asia Pacific sales with improvement in US and EMEA instrument revenue.
CEO's Statement
Dr. Wenbin Jiang, CEO, highlights strong execution and positioning for sustainable growth in the flow cytometry market.
- Cytek's Q4 2025 results show a positive trajectory with notable growth in key revenue segments.
- The return to positive growth in instrument sales in EMEA signifies a strategic milestone for the company.
Cytek Biosciences looks forward to reporting audited financial results for Q4 and full year 2025, setting the stage for providing 2026 financial guidance in the near future.